target directory

incretin effect modulation via amino acids and glp 1 on muscle microvascular blood flow and metabolism clinical trial intelligence

Trials are included when the normalized target field matches this target directory. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

1

Directory type

target

Association rule

normalized field

NCT02370745
Source recordAI-normalized

Characterizing the Incretin Effect of Amino Acids (AA) and Defining the Effect of GLP-1 on Muscle Microvascular Blood Flow and Muscle Protein and Glucose Metabolism in Older Age.

This study, sponsored by the University of Nottingham, investigates the effects of amino acids and GLP-1 on muscle metabolism and microvascular blood flow in younger and older adults. The findings could have significant implications for the treatment of sarcopenia and metabolic disorders, particularly in the aging population. Given the increasing prevalence of age-related muscle loss and metabolic diseases, there is a growing market for therapies targeting muscle health and metabolic regulation. The results may enhance the understanding of GLP-1's role beyond glucose regulation, potentially influencing the development of new therapeutic strategies or dietary supplements. Competitive implications include positioning against existing GLP-1 receptor agonists and other metabolic modulators, necessitating a thorough analysis of the data to assess differentiation and potential market entry strategies.

AI analysis

Indication: Sarcopenia

Modality: small molecule

Target: Incretin effect modulation via amino acids and GLP-1 on muscle microvascular blood flow and metabolism.

Sponsor: University of Nottingham

Source URL: ClinicalTrials.gov

Source updated: May 02, 2018

Ingested: Jun 19, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: Incretin effect modulation via amino acids and GLP-1 on muscle microvascular blood flow and metabolism.

View original source fields

Condition raw: Sarcopenia

Condition normalized: Sarcopenia

Modality raw: small molecule

Modality normalized: small molecule

Target raw: Incretin effect modulation via amino acids and GLP-1 on muscle microvascular blood flow and metabolism.

Target normalized: Incretin effect modulation via amino acids and GLP-1 on muscle microvascular blood flow and metabolism.

Open report